LBA105 Results from SunRISe-1 in patients (Pts) with bacillus Calmette–Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy-Reference-Cited by-同舟云学术

LBA105 Results from SunRISe-1 in patients (Pts) with bacillus Calmette–Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy

Published:2023-10 Issue: Volume:34 Page:S1343-S1344
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Necchi A.,Jacob J.M.,Daneshmand S.,Simone G.,Xylinas E.,Morris D.,Spiegelhalder P.,Zainfeld D.,Kang T.W.,Matulay J.T.,Belkoff L.,Decaestecker K.,Arentsen H.,Hampras S.,Cutie C.,Sweiti H.,Stromberg K.,Martin J.,Shukla A.,van der Heijden M.S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial;Journal of Urology;2024-07

2. Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial;Nature Medicine;2024-06-06

3. An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer;Expert Opinion on Biological Therapy;2024-06-02

4. Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient;American Society of Clinical Oncology Educational Book;2024-06

5. Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non–muscle-invasive Bladder Cancer;European Urology Oncology;2024-06